Published in Breast Cancer Res Treat on January 01, 1995
CORRELATIONSHIP OF CATHEPSIN D AND TOPOISOMERASE II ALPHA WITH NUCLEAR GRADING IN BREAST CANCERS. Med J Armed Forces India (2011) 0.75
Paclitaxel (taxol) N Engl J Med (1995) 5.79
Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol (2001) 5.17
Use of sodium taurocholate to enhance spore recovery on a medium selective for Clostridium difficile. J Clin Microbiol (1982) 4.35
The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther (2007) 4.33
Hypersensitivity reactions from taxol. J Clin Oncol (1990) 3.83
The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000) 3.40
Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol (2001) 3.27
Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol (1993) 3.18
Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst (1990) 3.09
Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Intern Med (1989) 2.81
A let-7 microRNA-binding site polymorphism in 3'-untranslated region of KRAS gene predicts response in wild-type KRAS patients with metastatic colorectal cancer treated with cetuximab monotherapy. Ann Oncol (2010) 2.39
Marked inactivation of O6-alkylguanine-DNA alkyltransferase activity with protracted temozolomide schedules. Br J Cancer (2003) 2.38
Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines. J Natl Cancer Inst (1996) 2.21
Sixteen-week dose-intense chemotherapy in the adjuvant treatment of breast cancer. J Natl Cancer Inst (1990) 2.15
The clinical pharmacology and use of antimicrotubule agents in cancer chemotherapeutics. Pharmacol Ther (1991) 2.06
Ecology of Candida albicans gut colonization: inhibition of Candida adhesion, colonization, and dissemination from the gastrointestinal tract by bacterial antagonism. Infect Immun (1985) 2.03
Successful re-treatment with taxol after major hypersensitivity reactions. J Clin Oncol (1993) 2.00
Microtubule changes and cytotoxicity in leukemic cell lines treated with taxol. Cancer Res (1988) 1.99
The current status of camptothecin analogues as antitumor agents. J Natl Cancer Inst (1993) 1.84
High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America. J Clin Oncol (1997) 1.75
Absorption, metabolism, and excretion of 14C-temozolomide following oral administration to patients with advanced cancer. Clin Cancer Res (1999) 1.64
Peripheral neuropathy from taxol and cisplatin combination chemotherapy: clinical and electrophysiological studies. Ann Neurol (1994) 1.57
Phase I and pharmacologic study of the tyrosine kinase inhibitor SU101 in patients with advanced solid tumors. J Clin Oncol (1999) 1.56
Neurotoxicity of Taxol. J Natl Cancer Inst Monogr (1993) 1.53
Factors correlated with progression-free survival after high-dose chemotherapy and hematopoietic stem cell transplantation for metastatic breast cancer. JAMA (1999) 1.49
A Phase I clinical and pharmacological evaluation of sodium phenylbutyrate on an 120-h infusion schedule. Clin Cancer Res (2001) 1.49
Cardiac disturbances during the administration of taxol. J Clin Oncol (1991) 1.46
A phase I and pharmacologic evaluation of the DNA intercalator CI-958 in patients with advanced solid tumors. Clin Cancer Res (2000) 1.45
High-dose chemotherapy of breast cancer: is the question answered? J Clin Oncol (1995) 1.43
Effect of various antibiotics on gastrointestinal colonization and dissemination by Candida albicans. Sabouraudia (1985) 1.43
A phase II "window" study of topotecan in untreated patients with high risk adult acute lymphoblastic leukemia. Clin Cancer Res (1998) 1.42
Inactivation of Serpulina hyodysenteriae flaA1 and flaB1 periplasmic flagellar genes by electroporation-mediated allelic exchange. J Bacteriol (1995) 1.42
Identification of Pasteurella multocida virulence genes in a septicemic mouse model using signature-tagged mutagenesis. Microb Pathog (2000) 1.42
Clinical and pharmacologic reappraisal of dichloromethotrexate. J Natl Cancer Inst (1988) 1.40
Phase I and pharmacologic study of paclitaxel and cisplatin with granulocyte colony-stimulating factor: neuromuscular toxicity is dose-limiting. J Clin Oncol (1993) 1.35
A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res (2001) 1.34
Phase I and pharmacodynamic study of taxol in refractory acute leukemias. Cancer Res (1989) 1.31
Sequences of topotecan and cisplatin: phase I, pharmacologic, and in vitro studies to examine sequence dependence. J Clin Oncol (1996) 1.28
Adhesion and association mechanisms of Candida albicans. Curr Top Med Mycol (1988) 1.24
Tumour gene expression predicts response to cetuximab in patients with KRAS wild-type metastatic colorectal cancer. Br J Cancer (2011) 1.24
A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest (2000) 1.20
Effect of P-glycoprotein expression on the accumulation and cytotoxicity of topotecan (SK&F 104864), a new camptothecin analogue. Cancer Res (1992) 1.19
Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest (1995) 1.18
Metabolic syndrome, central obesity and insulin resistance are associated with adverse pathological features in postmenopausal breast cancer. Clin Oncol (R Coll Radiol) (2010) 1.17
Fatigue, pain, and depression in pre-autotransplant breast cancer patients. Cancer Pract (2000) 1.16
Dual flaA1 flaB1 mutant of Serpulina hyodysenteriae expressing periplasmic flagella is severely attenuated in a murine model of swine dysentery. Infect Immun (1996) 1.16
Altered formation of topotecan-stabilized topoisomerase I-DNA adducts in human leukemia cells. Blood (1997) 1.15
Pathological and molecular predictors of the response of rectal cancer to neoadjuvant radiochemotherapy. Eur J Surg Oncol (2005) 1.13
A bioavailability and pharmacokinetic study of oral and intravenous hydroxyurea. Blood (1998) 1.13
Phase I and pharmacokinetic study of temozolomide on a daily-for-5-days schedule in patients with advanced solid malignancies. J Clin Oncol (1999) 1.11
The effectiveness of the comprehensive coping strategy program on clinical outcomes in breast cancer autologous bone marrow transplantation. Cancer Nurs (2000) 1.11
Phase I and pharmacologic studies of pyrazoloacridine, a novel DNA intercalating agent, on single-dosing and multiple-dosing schedules. J Clin Oncol (1995) 1.09
Activity of multitargeted antifolate (pemetrexed disodium, LY231514) in patients with advanced colorectal carcinoma: results from a phase II study. Cancer (2000) 1.06
Phase I trial of taxol in patients with advanced cancer. Cancer Treat Rep (1987) 1.05
Phase I and pharmacologic study of topotecan in patients with impaired renal function. J Clin Oncol (1996) 1.05
Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. J Clin Oncol (1994) 1.04
Identification of Actinobacillus pleuropneumoniae virulence genes using signature-tagged mutagenesis in a swine infection model. Microb Pathog (2000) 1.04
Phase I and pharmacological study of the novel topoisomerase I inhibitor 7-ethyl-10-[4-(1-piperidino)-1-piperidino]carbonyloxycamptothecin (CPT-11) administered as a ninety-minute infusion every 3 weeks. Cancer Res (1994) 1.04
Phase I and pharmacokinetic study of the oral fluoropyrimidine capecitabine in combination with paclitaxel in patients with advanced solid malignancies. J Clin Oncol (1999) 1.02
Evaluation of ivermectin on performance of beef cattle on pasture in alberta. Can Vet J (1988) 1.02
Taxol toxicity. Epithelial necrosis in the gastrointestinal tract associated with polymerized microtubule accumulation and mitotic arrest. Cancer (1989) 1.01
High-performance liquid chromatographic assay for taxol in human plasma and urine and pharmacokinetics in a phase I trial. Cancer Treat Rep (1987) 1.00
Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II. Clin Cancer Res (1998) 1.00
Phase II study of flavopiridol in patients with advanced colorectal cancer. Ann Oncol (2003) 0.99
Phase I and pharmacological study of the pulmonary cytotoxin 4-ipomeanol on a single dose schedule in lung cancer patients: hepatotoxicity is dose limiting in humans. Cancer Res (1993) 0.99
Erlotinib 'dosing-to-rash': a phase II intrapatient dose escalation and pharmacologic study of erlotinib in previously treated advanced non-small cell lung cancer. Br J Cancer (2011) 0.99
The clinical status of irinotecan (CPT-11), a novel water soluble camptothecin analogue: 1996. Crit Rev Oncol Hematol (1996) 0.99
Multiple lymphomatous polyposis of the gastrointestinal tract. A clinicopathologically distinctive form of non-Hodgkin's lymphoma of B-cell centrocytic type. Am J Surg Pathol (1989) 0.99
Phase I study of non-replicating autologous tumor cell injections using cells prepared with or without GM-CSF gene transduction in patients with metastatic renal cell carcinoma. Hum Gene Ther (1995) 0.98
Angiostrongylosis with disseminated larval infection associated with signs of ocular and nervous disease in an imported dog. Can Vet J (1991) 0.98
Tumor targeting by conjugation of DHA to paclitaxel. J Control Release (2001) 0.98
Impact of the putative differentiating agent sodium phenylbutyrate on myelodysplastic syndromes and acute myeloid leukemia. Clin Cancer Res (2001) 0.98
Intensified adjuvant combined modality therapy for resected periampullary adenocarcinoma: acceptable toxicity and suggestion of improved 1-year disease-free survival. Int J Radiat Oncol Biol Phys (2000) 0.98
A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol (2003) 0.97
A Phase I and pharmacokinetic study of temozolomide and cisplatin in patients with advanced solid malignancies. Clin Cancer Res (1999) 0.97
Population pharmacokinetic model for topotecan derived from phase I clinical trials. J Clin Oncol (2000) 0.95
Phase I and pharmacokinetic study of BMS-184476, a taxane with greater potency and solubility than paclitaxel. J Clin Oncol (2001) 0.95
Hepatic metabolism and biliary excretion of Taxol in rats and humans. J Natl Cancer Inst Monogr (1993) 0.95
Staphylococcal exotoxins stimulate nitric oxide-dependent murine macrophage tumoricidal activity. Infect Immun (1991) 0.95
Feasibility and efficacy of a supervised exercise intervention in de-conditioned cancer survivors during the early survivorship phase: the PEACH trial. J Cancer Surviv (2013) 0.94
A Phase I and pharmacological study of the glutamine antagonist acivicin with the amino acid solution aminosyn in patients with advanced solid malignancies. Clin Cancer Res (1998) 0.94
Sequence-dependent cytotoxic effects due to combinations of cisplatin and the antimicrotubule agents taxol and vincristine. J Cancer Res Clin Oncol (1993) 0.94
Oral paclitaxel and concurrent cyclosporin A: targeting clinically relevant systemic exposure to paclitaxel. Clin Cancer Res (2000) 0.93
Taxol: twenty years later, the story unfolds. J Natl Cancer Inst (1991) 0.93
A phase I and pharmacokinetic study of the mitochondrial-specific rhodacyanine dye analog MKT 077. Clin Cancer Res (2000) 0.93
Detection of tumor cells in the bone marrow, peripheral blood, and apheresis products of breast cancer patients using flow cytometry. Exp Hematol (1995) 0.93